Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression

Journal of Leukocyte Biology

Volumn 83, Issue 4, 2008, Pages 1049-1059

  Larmonier, Nicolas ^a   Cantrell, Jessica ^a   LaCasse, Collin ^a   Li, Gang ^a   Janikashvili, Nona ^a   Situ, Elaine ^a   Sepassi, Marjan ^a   Andreansky, Samita ^a   Katsanis, Emmanuel ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

CD4+CD25+ regulatory T lymphocytes; Chaperone rich cell lysate; Dendritic cells; Monocytes macrophages

Indexed keywords

CHAPERONE; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL LYSATE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; LEUKEMIA; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR CELL; ANIMAL; BONE MARROW CELL; EXPERIMENTAL LEUKEMIA; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; PATHOLOGY; PERITONEUM MACROPHAGE; TUMOR CELL LINE;

MUS;

ANIMALS; BONE MARROW CELLS; CELL LINE, TUMOR; DENDRITIC CELLS; IMMUNOSUPPRESSION; LEUKEMIA, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MACROPHAGES, PERITONEAL; MICE; NF-KAPPA B; T-LYMPHOCYTES, REGULATORY;

EID: 44449112373     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0907635     Document Type: Article

References (61)

1. Asano, M., Toda, M., Sakaguchi, N., Sakaguchi, S. (1996) Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184, 387-396.
2. Sakaguchi, S. (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562.
3. Sakaguchi, S. (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455-458.
4. Shevach, E. M., DiPaolo, R. A., Andersson, J., Zhao, D. M., Stephens, G. L., Thornton, A. M. (2006) The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212, 60-73.
5. Fontenot, J. D., Gavin, M. A., Rudensky, A. Y. (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336.
6. Fontenot, J. D., Rudensky, A. Y. (2005) A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6, 331-337.
7. Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., Rudensky, A. Y. (2007) Foxp3-dependent program of regulatory T-cell differentiation. Nature 445, 771-775.
8. Sakaguchi, S. (2005) Naturally arising Foxp3-expressing CD25(+)CD4(+) regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6, 345-352.
9. Shevach, E. M. (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400.
10. Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., Strober, W. (2004) TGF-β 1 plays an important role in the mechanism of CD49+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172, 834-842.
11. Nakamura, K., Kitani, A., Strober, W. (2001) Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194, 629-644.
12. Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., Rudensky, A. Y. (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329-341.
13. Piccirillo, C. A., Letterio, J. J., Thornton, A. M., McHugh, R. S., Mamura, M., Mizuhara, H., Shevach, E. M. (2002) CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor β1 production and responsiveness. J. Exp. Med. 196, 237-246.
14. Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C. C., Klebanoff, C. A., Overwijk, W. W., Rosenberg, S. A., Restifo, N. P. (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601.
15. Shimizu, J., Yamazaki, S., Sakaguchi, S. (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218.
16. Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., June, C. H. (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272-4276.
17. Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., Martin, F. (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336-344.
18. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., Linehan, D. C. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761.
19. Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E., Offringa, R., Melief, C. J. (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823-832.
20. Hussain, S. F., Paterson, Y. (2004) CD4+CD25+ regulatory T cells that secrete TGFβ and IL-10 are preferentially induced by a vaccine vector. J. Immunother. 27, 339-346.
21. Viguier, M., Lemaitre, F., Verola, O., Cho, M. S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., Ferradini, L. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444-1453.
22. Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., Fu, Y. X. (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201, 779-791.
23. Prasad, S. J., Farrand, K. J., Matthews, S. A., Chang, J. H., McHugh, R. S., Ronchese, F. (2005) Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J. Immunol. 174, 90-98.
24. Dannull, J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., Zhang, A., Dahm, P., Chao, N., Gilboa, E., Vieweg, J. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115, 3623-3633.
25. Nishikawa, H., Jager, E., Ritter, G., Old, L. J., Gnjatic, S. (2005) CD4 CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 106, 1008-1111.
26. Somasundaram, R., Jacob, L., Swoboda, R., Caputo, L., Song, H., Basak, S., Monos, D., Peritt, D., Marincola, F., Cai, D., et al. (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 62, 5267-5272.
27. Cederbom, L., Hall, H., Ivars, F. (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 30, 1538-1543.
28. Houot, R., Perrot, I., Garcia, E., Durand, I., Lebecque, S. (2006) Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J. Immunol. 176, 5293-5298.
29. Misra, N., Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M. D., Kaveri, S. V. (2004) Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J. Immunol. 172, 4676-4680.
30. Taams, L. S., van Amelsfort, J. M., Tiemessen, M. M., Jacobs, K. M., de Jong, E. C., Akbar, A. N., Bijlsma, J. W., Lafeber, F. P. (2005) Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum. Immunol. 66, 222-230.
31. Larmonier, N., Marron, M., Zeng, Y., Cantrell, J., Romanoski, A., Sepassi, M., Thompson, S., Chen, X., Andreansky, S., Katsanis, E. (2007) Tumor-derived CD4(+)CD25 (+) regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol. Immunother. 56, 48-59.
32. Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M. L., Puccetti, P. (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4, 1206-1212.
33. Graner, M. W., Zeng, Y., Feng, H., Katsanis, E. (2003) Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother. 52, 226-234.
34. Zeng, Y., Chen, X., Larmonier, N., Larmonier, C., Li, G., Sepassi, M., Marron, M., Andreansky, S., Katsanis, E. (2006) Natural killer cells play a key role in the anti-tumor immunity generated by chaperone rich cell lysate vaccination. Int. J. Cancer 119, 2624-2631.
35. Zeng, Y., Graner, M. W., Feng, H., Li, G., Katsanis, E. (2004) Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int. J. Cancer 110, 251-259.
36. Graner, M., Raymond, A., Akporiaye, E., Katsanis, E. (2000) Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol. Immunother. 49, 476-484.
37. Graner, M., Raymond, A., Romney, D., He, L., Whitesell, L., Katsanis, E. (2000) Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin. Cancer Res. 6, 909-915.
38. Zeng, Y., Feng, H., Graner, M. W., Katsanis, E. (2003) Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101, 4485-4491.
39. Bonnotte, B., Larmonier, N., Favre, N., Fromentin, A., Moutet, M., Martin, M., Gurbuxani, S., Solary, E., Chauffert, B., Martin, F. (2001) Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J. Immunol. 167, 5077-5083.
40. Klimp, A. H., de Vries, E. G., Scherphof, G. L., Daemen, T. (2002) A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol. 44, 143-161.
41. He, L., Feng, H., Raymond, A., Kreeger, M., Zeng, Y., Graner, M., Whitesell, L., Katsanis, E. (2001) Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol. Immunother. 50, 31-40.
42. Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Menard, C., Ghiringhelli, F., Terme, M., Carpentier, A. F., Darrasse-Jeze, G., Lemonnier, F., Zitvogel, L. (2006) Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176, 2722-2729.
43. Knutson, K. L., Dang, Y., Lu, H., Lukas, J., Almand, B., Gad, E., Azeke, E., Disis, M. L. (2006) IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177, 84-91.
44. Comes, A., Rosso, O., Orengo, A. M., Di Carlo, E., Sorrentino, C., Meazza, R., Piazza, T., Valzasina, B., Nanni, P., Colombo, M. P., Ferrini, S. (2006) CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176, 1750-1758.
45. Valzasina, B., Piconese, S., Guiducci, C., Colombo, M. P. (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25-lymphocytes is thymus and proliferation independent. Cancer Res. 66, 4488-4495.
46. Steinbrink, K., Jonuleit, H., Muller, G., Schuler, G., Knop, J., Enk, A. H. (1999) Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93, 1634-1642.
47. Kuwana, M. (2002) Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum. Immunol. 63, 1156-1163.
48. Gabrilovich, D. (2004) Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952.
49. Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., Gabrilovich, D. I. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689.
50. Monti, P., Leone, B. E., Zerbi, A., Balzano, G., Cainarca, S., Sordi, V., Pontillo, M., Mercalli, A., Di Carlo, V., Allavena, P., Piemonti, L. (2004) Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J. Immunol. 172, 7341-7349.
51. Verginis, P., Li, H. S., Carayanniotis, G. (2005) Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J. Immunol. 174, 7433-7439.
52. Mahnke, K., Qian, Y., Knop, J., Enk, A. H. (2003) Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101, 4862-4869.
53. Feng, H., Zeng, Y., Graner, M. W., Likhacheva, A., Katsanis, E. (2003) Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 101, 245-252.
54. Sato, K., Tateishi, S., Kubo, K., Mimura, T., Yamamoto, K., Kanda, H. (2005) Downregulation of IL-12 and a novel negative feedback system mediated by CD25(+)CD4(+) T cells. Biochem. Biophys. Res. Commun. 330, 226-232.
55. Almand, B., Resser, J. R., Lindman, B., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., Gabrilovich, D. I. (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766.
56. Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., Lackner, A., Alvarez, X., Ochoa, A., Chen, L., Zou, W. (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881.
57. Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., Hill, A. M. (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164, 6166-6173.
58. Pollard, J. W. (2004) Tumor-educated macrophages promote tumor progression and metastasis. Nat. Rev. Cancer 4, 71-78.
59. Sinha, P., Clements, V. K., Ostrand-Rosenberg, S. (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174, 636-645.
60. Jarnicki, A. G., Lysaght, J., Todryk, S., Mills, K. H. (2006) Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177, 896-904.
61. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B., Palucka, K. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811.